Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andrx settles Glucotrol infringement suit

Executive Summary

Andrx agrees with Pfizer and Alza to settle patent infringement litigation over the company's ANDA for a generic version of Glucotrol XL (glipizide extended release). All claims were dropped with Andrx agreeing to receive a royalty-bearing sublicense under relevant Alza patents. Andrx believes it was first to file a glipizide ANDA. Andrx filed a citizen's petition with FDA related to the case in November (1"The Pink Sheet" Nov. 11, 2002, p. 25)...
Advertisement

Related Content

Pfizer Glucotrol XL Patent Should Be Deemed Late Listed – Andrx
Pfizer Glucotrol XL Patent Should Be Deemed Late Listed – Andrx
Advertisement
UsernamePublicRestriction

Register

PS042412

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel